EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparison of Clinical and Angiographic Outcomes of Ranibizumab and Aflibercept in Type 1 and Aggressive Retinopathy of Prematurity

Wenting Zhang, Haonan Ma, Jianhui Wang, Zhijun Chen, Xuerui Zhang, Haodong Xiao, Huanyu Liu, Yuan Yang, Jiawei Yin, Mingyang Wang, Jie Peng, Yu Xu und 1 weitere

Clinical & Experimental Ophthalmology · 2025

DOI: 10.1111/ceo.14575 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical & Experimental Ophthalmology, 2025. Verfasst von Wenting Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Ranibizumab, Retinopathy of Prematurity, Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Natural Science Foundation of China, The Construction Project of the "Discipline Peak-Climbing Plan" of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To compare the clinical and angiographic outcomes of aggressive retinopathy of prematurity (A‐ROP) and type 1 retinopathy of prematurity (ROP) treated with intravitreal injection of ranibizumab (IVR) or aflibercept (IVA).

Methods

This retrospective, non‐randomised study included a consecutive series of patients with type 1 ROP or A‐ ROP who initially treated with ranibizumab (0.25 mg/0.025 mL) or aflibercept (1.0 mg/0.025 mL) between October 2017 and November 2020. Clinical data and long‐term vascular characteristics were analysed.

Results

A total of 297 eyes of 151 infants were included. Compared to IVA, IVR was a significant risk factor for reactivation in multivariate regression analysis. The risk time of reactivation in A‐ROP and Type 1 Zone I ROP was shorter in the IVR group ( p < 0.001). Fewer injections were required in the IVA group for patients with A‐ROP and Type 1 Zone I ROP ( p = 0.012). More vascular abnormalities were observed in the IVA group during reactivation, with increased arteriovenous shunting ( p = 0.028) in Type 1 Zone II ROP and more tortuosity ( p = 0.047), dilation ( p = 0.047) and plus disease ( p = 0.020) in Type 1 Zone I ROP and A‐ROP. In fundus fluorescein angiography, staining of the vessel wall and telangiectasia were more frequent in the IVA group.

Conclusions

Ranibizumab treatment was associated with a higher rate of reactivation and a shorter risk period for reactivation compared to aflibercept, potentially requiring more frequent injections, though some differences did not reach statistical significance. However, there were more signs of vascular abnormalities after receiving aflibercept treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RanibizumabRetinopathy of PrematurityReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsFluorescein AngiographyRetinal VesselsHumansIntravitreal InjectionsRetrospective StudiesFemaleMaleAngiogenesis InhibitorsInfant, NewbornGestational AgeTreatment OutcomeVascular Endothelial Growth Factor AFollow-Up StudiesFundus OculiInfant

Stichwörter der Autor:innen

afliberceptfluorescein fundus angiography (FFA)ranibizumabreactivationretinopathy of prematurity (ROP)

Substanzen

afliberceptRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsAngiogenesis InhibitorsVascular Endothelial Growth Factor AVEGFA protein, human

Autor:innen und Institutionen

  • Department of Ophthalmology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Shanghai Jiao Tong University School of Medicine, Shanghai, China.

ORCID-Profile: Peiquan Zhao

Förderung

  • National Natural Science Foundation of China
  • The Construction Project of the "Discipline Peak-Climbing Plan" of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Zitieren

APA

Zhang, W., Ma, H., Wang, J., Chen, Z., Zhang, X., Xiao, H., Liu, H., Yang, Y., Yin, J., Wang, M., Peng, J., Xu, Y., & Zhao, P. (2025). Comparison of Clinical and Angiographic Outcomes of Ranibizumab and Aflibercept in Type 1 and Aggressive Retinopathy of Prematurity. Clinical & Experimental Ophthalmology. https://doi.org/10.1111/ceo.14575

Vancouver

Zhang W, Ma H, Wang J, Chen Z, Zhang X, Xiao H, et al. Comparison of Clinical and Angiographic Outcomes of Ranibizumab and Aflibercept in Type 1 and Aggressive Retinopathy of Prematurity. Clinical & Experimental Ophthalmology. 2025. doi:10.1111/ceo.14575

BibTeX
@article{Zhang2025,
  author = {Zhang, Wenting and Ma, Haonan and Wang, Jianhui and Chen, Zhijun and Zhang, Xuerui and Xiao, Haodong and Liu, Huanyu and Yang, Yuan and Yin, Jiawei and Wang, Mingyang and Peng, Jie and Xu, Yu and Zhao, Peiquan},
  title = {Comparison of Clinical and Angiographic Outcomes of Ranibizumab and Aflibercept in Type 1 and Aggressive Retinopathy of Prematurity},
  journal = {Clinical & Experimental Ophthalmology},
  year = {2025},
  doi = {10.1111/ceo.14575}
}
Kostenlos starten →